---
title: "BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289522339.md"
description: "BeOne Medicines Ltd (HK:6160) filed a Form S-8 with the U.S. SEC to register shares under its equity incentive plans, enhancing global compensation capabilities. The company is a Swiss-incorporated biopharmaceutical firm listed in Hong Kong. Analysts maintain a 'Buy' rating with a HK$243.80 price target, while technical signals indicate a 'Sell'."
datetime: "2026-06-11T23:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289522339.md)
  - [en](https://longbridge.com/en/news/289522339.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289522339.md)
---

# BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans

An announcement from BeOne Medicines Ltd ( (HK:6160) ) is now available.

BeOne Medicines Ltd., a Swiss-incorporated biopharmaceutical company listed in Hong Kong, has filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission. The filing covers shares issuable under its Fifth Amended and Restated 2016 Share Option and Incentive Plan and its Sixth Amended and Restated 2018 Employee Share Purchase Plan.

By registering these securities in the U.S., BeOne enhances its ability to grant equity-based compensation to employees and participants in its global operations. The move underscores the company’s maturation as a cross-border public issuer and may support talent retention and alignment of management and staff incentives with shareholder interests.

The most recent analyst rating on (HK:6160) stock is a Buy  
with a HK$243.80 price target.  
To see the full list of analyst forecasts on BeOne Medicines Ltd stock,  
see the HK:6160 Stock Forecast page.

**More about BeOne Medicines Ltd**

BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange under stock code 06160. The company operates through entities in Switzerland and the U.S., including BeOne Medicines I GmbH in Basel and BeOne Medicines USA, Inc. in Cambridge, Massachusetts, reflecting a transatlantic footprint in drug development and related life sciences activities.

**Average Trading Volume:** 4,577,000

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$242.5B

For a thorough assessment of 6160 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)

## Related News & Research

- [BeOne Medicines Shareholders Approve All AGM Resolutions and Refresh Board](https://longbridge.com/en/news/289523357.md)
- [BeOne Medicines President Trades $368K In Company Stock](https://longbridge.com/en/news/289485035.md)
- [BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance](https://longbridge.com/en/news/289523795.md)
- [Insider Unloading: Henry Chan Lee Sells $235K Worth Of BeOne Medicines Shares](https://longbridge.com/en/news/289485046.md)
- [BeOne Medicines Chief Executive Officer Sold Shares Worth Over $1.3M](https://longbridge.com/en/news/289380401.md)